Clay Siegall has cemented his status as one of the leading scientists in cancer therapy in the U.S. His immense experience and vast knowledge have earned him admiration and respect from his peers and colleagues from various walks of life.
Clay Siegall’s Role at Seattle Genetics
For over a decade, cancer has been a nagging disorder to most patients. Not only are they robbed off good health but they also have to settle huge medical bills accrued in various medical centers. Mr. Siegall deemed it necessary to develop Seattle Genetics in 1998, with the sole purpose of spearheading research on cancer therapies. By serving as the company’s CEO and Chairman of the Board, he has remarkably invigorated research training & techniques and expedited the development of drug practices. While at the helm, he is credited with pioneering the development of ADCs such as ADCETRIS, which is now a global brand across 60 countries worldwide.
By yielding positive results, ADCETRIS has instigated the development of other cancer remedies which are currently in the company’s pipeline. Additionally, Siegall has also played a valuable role in the generation of $ 325 million courtesy of lucrative contracts with leading clinical firms across the medical realm. Companies such as GlaxoSmithKline and Pfizer and Genentech have lauded the positive impacts made by the formidable partnership. An additional $1.2 billion has also been raised courtesy of private and public rounds of financing.
Clay Siegall’s Role in the Cancer Research Community
Having developed ADCETRIS, Siegall has embarked on a groundbreaking mission to broaden the drug’s application across numerous patients. The highly publicized campaign aims at establishing Seattle Genetics as the core cancer therapy institution in the U.S. According to Siegall, the clinical drug is currently under experiment in over 70 lymphoma patients with the anticipation of positive results. Based on recent findings, the clinical trial has yielded positive results in the diagnosis of Hodgkin lymphoma. With such results, ADCETRIS has eclipsed any achievement made in the year.
Apart from the research exploits, Siegall has also launched an ambitious plan to hire an additional 100 employees to supplement the development of 12 more clinical cancer therapies.